William (Bill) Doyle is the executive chairman of Novocure, a commercial-stage oncology company which is currently developing Tumor Treating Fields, a new therapy for solid tumor cancers. He is also a managing partner of venture capital investor WFD Ventures LLC.
Previously, Bill served as an executive at Johnson & Johnson, where he served on the Consumer Pharmaceuticals and Medical Devices Group Operating Committees, and as the vice president of Licensing and Acquisitions. Earlier in his career, Bill provided consultation insights at McKinsey & Company. He received his bachelor’s degree in materials science and engineering from the Massachusetts Institute of Technology and an M.B.A. from Harvard Business School.
Speaking of his third- and second-generation Irish heritage, he says his father’s side dates a little farther back than his mother’s. “The first to come to America was Owen Doyle, who emigrated from Co. Carlow in about 1843 and arrived in Nova Scotia.” Bill’s maternal grandparents were both originally from Belfast. After emigrating, they met by chance in Boston and were married in 1898, where the family has remained ever since.